Companies · CRSP
CRISPR Therapeutics
AI-generated · informational only · not investment advice · verify before relying.
Latest analysis
Updated Aug 3, 2026
CRSP reports 78% QoQ CASGEVY revenue growth to $76M; expands pipeline with Phase 1 initiation in hypertension and AATD
CRISPR Therapeutics delivered CASGEVY revenue of $76 million in Q2 2026, representing 78% sequential growth and 151% year-over-year increase, driven by FDA approval for children as young as 2 years old and reimbursement expansion in Germany. The company advanced its in vivo pipeline with Phase 1 initiation for CTX340 (refractory hypertension) and CTX460 (alpha-1 antitrypsin deficiency), while continuing Phase 1 development of zugo-cel across multiple autoimmune and hematologic indications. Net loss narrowed substantially to $91.2 million in Q2 2026 from $208.5 million in Q2 2025, with cash position strengthened to $2.36 billion through convertible debt issuance in March 2026.
Tone: bullishRevenue
$3.5M
CRSP 10-K · FY 2025
Revenue FY2024
$37.3M
Headquarters
Zug, Switzerland
Profile
CRSP 10-K Item 1 · Feb 12, 2026CRISPR Therapeutics AG is a Swiss-incorporated biopharmaceutical company focused on developing CRISPR/Cas9-based gene-editing therapeutics for serious diseases. Its most advanced product, CASGEVY, is the world's first approved CRISPR therapy, co-developed and co-commercialized with Vertex Pharmaceuticals for sickle cell disease and transfusion-dependent beta thalassemia. The company is advancing a pipeline spanning in vivo liver editing, allogeneic CAR T cell therapy, siRNA programs, and regenerative medicine.
Read filing description ↓ Collapse description ↑
Our mission is to create transformative gene-based medicines for serious human diseases. We are a leading biopharmaceutical company focused on the development of CRISPR-based therapeutics, including by using CRISPR/Cas9 technology. CRISPR/Cas9 is a revolutionary technology for gene editing, the process of precisely altering specific sequences of genomic DNA. We have advanced this technology from discovery to an approved medicine with unparalleled speed, culminating in the landmark first approval of a CRISPR-based therapy, CASGEVY (exagamglogene autotemcel [exa-cel]), in 2023 with our collaborators at Vertex Pharmaceuticals Incorporated, or Vertex. We have established a portfolio of therapeutic programs spanning four core franchises: hemoglobinopathies, in vivo, CAR T approaches and regenerative medicine. Depending on the program, we take either an ex vivo approach, in which we edit cells outside of the human body before administering them to the patient, or an in vivo editing approach, where we deliver the CRISPR-based therapeutic directly to target cells within the human body. We continue to innovate on our platform to develop next-generation technologies that can enable new therapies. We are developing other technologies, including delivery technologies and other gene editing technologies, like SyNTase. Through our efforts, we aim to unlock the full potential of gene-based therapeutics to create medicines that can transform people's lives. We believe that our innovative research, translational expertise, and clinical development experience, position us as a leader in the development of CRISPR-based therapeutics and may enable us to create an entirely new class of highly effective and potentially curative therapies for patients with both common and rare diseases for whom current biopharmaceutical approaches have had limited success.
Primary products
- CASGEVY (exagamglogene autotemcel [exa-cel])
- zugocabtagene geleucel (zugo-cel; formerly CTX112)
- CTX310
- CTX611 (formerly SRSD107)
- CTX340
- CTX321
Business segments
End markets
Geographies
Named customers
Named competitors
“We believe that our technology, development experience and scientific knowledge provide us with competitive advantages, we currently face, and will continue to face, substantial competition from many different sources, including large pharmaceutical, specialty pharmaceutical and biotechnology companies; academic institutions and governmental agencies; and public and private research institutions, some or all of which may have greater access to capital or resources than we do.” Competitive position, as stated in the filing
Revenue commentary · FY 2025
Total revenue fell sharply in 2025 to $3.5 million from $37.3 million in 2024, driven by the absence of any collaboration revenue in 2025 versus $35.0 million in collaboration revenue in 2024, with only grant revenue of $3.5 million recognized in 2025.
The rest of CRSP is for subscribers
Analysis, signals, diligence answers, M&A activity and every quote, each citing the filing it came from.